Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy
Arq. bras. oftalmol
;
87(2): e2023, 2024. tab
Artículo
en Inglés
|
LILACS-Express
| LILACS
| ID: biblio-1533796
ABSTRACT
ABSTRACT Purpose:
To investigate the clinical benefits of the co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy.Methods:
Patients who underwent vitrectomy for proliferative dia-betic retinopathy complications were preoperatively given in-travitreal injection with either bevacizumab and tissue plasminogen activator (Group 1) or bevacizumab alone (Group 2). Primary outcomes were surgery time and number of intraoperative iatrogenic retinal breaks. Secondary outcomes included changes in the best-corrected visual acuity and postoperative complications at 3 months postoperatively.Results:
The mean surgery time in Group 1 (52.95 ± 5.90 min) was significantly shorter than that in Group 2 (79.61 ± 12.63 min) (p<0.001). The mean number of iatrogenic retinal breaks was 0.50 ± 0.59 (0-2) in Group 1 and 2.00 ± 0.83 (0-3) in Group 2 (p<0.001). The best-corrected visual acuity significantly improved in both groups (p<0.001). One eye in each group developed retinal detachment.Conclusion:
Preoperative co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy shortens the surgery time and reduces the number of intraoperative iatrogenic retinal breaks.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Idioma:
Inglés
Revista:
Arq. bras. oftalmol
Asunto de la revista:
Oftalmología
Año:
2024
Tipo del documento:
Artículo
País de afiliación:
Turquía
/
Reino Unido
Institución/País de afiliación:
Istanbul Medipol University/TR
/
The Princess Alexandra Hospital NHS Trust/GB
/
Yeditepe University/TR
Similares
MEDLINE
...
LILACS
LIS